Instil Bio, Inc.
NASDAQ:TIL
20.35 (USD) • At close January 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 7.67 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.052 | 0.042 | 0.044 |
| Cost of Revenue
| 0 | 1 | 0.993 | 1.036 | 0.953 | 0.835 | 2.047 | 0.807 | 2.405 | 0.979 | 1.796 | 0.893 | 0.764 | 0.656 | 0.439 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | -1 | -0.993 | 6.634 | -0.953 | -0.835 | -2.047 | -0.807 | -2.405 | -0.979 | -1.796 | -0.893 | -0.764 | -0.656 | -0.439 | 0 | 0.052 | 0.042 | 0.044 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0.865 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 10 | 2.921 | 7.256 | 1.983 | 8.492 | 8.459 | 20.67 | 20.722 | 39.66 | 41.5 | 39.174 | 42.577 | 29.064 | 21.186 | 14.424 | 10.247 | 4.908 | 2.237 | 2.007 |
| General & Administrative Expenses
| 10.707 | 10.706 | 12.424 | 10.872 | 11.941 | 11.518 | 13.222 | 12.91 | 16.989 | 17.224 | 15.112 | 11.175 | 13.96 | 14.195 | 8.979 | 7.23 | 2.855 | 2.398 | 1.9 |
| Selling & Marketing Expenses
| 0 | 0 | -0.993 | -1.036 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 10.707 | 10.706 | 11.431 | 9.836 | 11.941 | 11.518 | 13.222 | 12.91 | 16.989 | 17.224 | 15.112 | 11.175 | 13.96 | 14.195 | 8.979 | 7.23 | 2.855 | 2.398 | 1.9 |
| Other Expenses
| 2.924 | -1 | -0.428 | -0.12 | 46.283 | 0.628 | -0.057 | 1.299 | -0.415 | -1.032 | -0.319 | -0.538 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 23.631 | 12.627 | 18.687 | 11.819 | 66.716 | 19.977 | 33.892 | 33.632 | 56.649 | 58.724 | 54.286 | 53.752 | 43.024 | 35.381 | 23.403 | 17.477 | 7.763 | 4.635 | 3.907 |
| Operating Income
| -23.631 | -13.627 | -19.68 | -12.855 | -66.716 | -20.987 | -58.446 | -56.799 | -56.649 | -58.724 | -54.286 | -53.752 | -43.024 | -35.381 | -23.403 | -17.477 | -7.711 | -4.593 | -3.863 |
| Operating Income Ratio
| 0 | 0 | 0 | -1.676 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -148.288 | -109.357 | -87.795 |
| Total Other Income Expenses Net
| 0.61 | -1.29 | -4.622 | -0.07 | -0.716 | 2.325 | 1.378 | 2.35 | 0.054 | -0.877 | -0.319 | -0.538 | -0.639 | -0.089 | 0.071 | 0.443 | 0.449 | -4.609 | -0.226 |
| Income Before Tax
| -23.021 | -14.917 | -24.302 | -12.925 | -67.432 | -18.662 | -57.068 | -54.449 | -56.595 | -59.601 | -54.605 | -54.29 | -43.663 | -35.47 | -23.332 | -17.034 | -7.262 | -9.202 | -4.089 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -1.685 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -139.654 | -219.095 | -92.932 |
| Income Tax Expense
| 0 | 0 | 0.95 | 1.468 | -0.953 | 0.227 | -0.742 | -0.605 | -0.371 | -0.609 | -0.488 | 1.06 | -0.658 | -0.159 | -0.204 | 0.151 | -0.449 | 4.609 | 0.226 |
| Net Income
| -23.021 | -14.917 | -24.302 | -12.925 | -67.432 | -18.662 | -56.326 | -53.844 | -56.224 | -58.992 | -54.117 | -55.35 | -43.005 | -35.311 | -23.128 | -17.185 | -7.262 | -9.202 | -4.089 |
| Net Income Ratio
| 0 | 0 | 0 | -1.685 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -139.654 | -219.095 | -92.932 |
| EPS
| -3.54 | -2.29 | -3.74 | -1.99 | -10.37 | -2.87 | -8.66 | -8.29 | -0.43 | -0.46 | -0.42 | -0.43 | -0.33 | -0.27 | -0.66 | -0.49 | -0.12 | -0.15 | -0.066 |
| EPS Diluted
| -3.54 | -2.29 | -3.74 | -1.99 | -10.37 | -2.87 | -8.66 | -8.29 | -0.43 | -0.46 | -0.42 | -0.43 | -0.33 | -0.27 | -0.66 | -0.49 | -0.12 | -0.15 | -0.066 |
| EBITDA
| -20.114 | -11.918 | -21.577 | -9.909 | -64.476 | -17.237 | -54.385 | -52.897 | -53.383 | -58.724 | -52.809 | -53.397 | -42.899 | -34.814 | -22.893 | -17.329 | -7.644 | -4.559 | -3.856 |
| EBITDA Ratio
| 0 | 0 | 0 | -1.541 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -147 | -108.548 | -87.636 |